First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement.
暂无分享,去创建一个
N. Svrzikapa | G. Shapiro | P. LoRusso | J. Tabernero | G. Schwartz | G. Hinkle | G. Weiss | M. Gounder | L. Paz-Ares | H. Burris | J. Infante | M. Alsina | D. Bumcrot | I. Toudjarska | D. Cho | J. Gollob | C. Gamba-Vitalo | D. Sah | A. Cervantes | R. Falzone | Jamie Harrop | A. C. White | R. Meyers | R. Hutabarat | Valerie A. Clausen | J. Cehelsky | S. Nochur | A. Vaishnaw | C. Gamba‐Vitalo
[1] Yechezkel Barenholz,et al. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. , 2011, Advanced drug delivery reviews.
[2] T. Efferth,et al. Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products. , 2011, Current medicinal chemistry.
[3] K. Leslie,et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] M. Kulke,et al. New Treatment Options for Patients with Advanced Neuroendocrine Tumors , 2011, Current treatment options in oncology.
[5] Y. Bang,et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. , 2011, The New England journal of medicine.
[6] D. Bumcrot,et al. Progress in the delivery of siRNA therapeutics: Potential in uveal melanoma , 2011, Drugs of the Future.
[7] R. Jain,et al. Delivering nanomedicine to solid tumors , 2010, Nature Reviews Clinical Oncology.
[8] John Maraganore,et al. A status report on RNAi therapeutics , 2010, Silence.
[9] V. Ravi,et al. Inhibiting the VEGF–VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor , 2010, Current opinion in oncology.
[10] K. G. Rajeev,et al. Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[11] Mark E. Davis,et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.
[12] Suzanne F. Jones,et al. A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors , 2011, Investigational New Drugs.
[13] Helen X. Chen,et al. Adverse effects of anticancer agents that target the VEGF pathway , 2009, Nature Reviews Clinical Oncology.
[14] A. Judge,et al. siRNA and innate immunity. , 2009, Oligonucleotides.
[15] A. Judge,et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. , 2009, The Journal of clinical investigation.
[16] S. Paggi,et al. Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .
[17] Robert Langer,et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates , 2008, Proceedings of the National Academy of Sciences.
[18] Wenfang Xu,et al. Progress on kinesin spindle protein inhibitors as anti-cancer agents. , 2008, Anti-cancer agents in medicinal chemistry.
[19] G. Pond,et al. Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck , 2008, Investigational New Drugs.
[20] Liz Y. Han,et al. Clinical and Biological Significance of Vascular Endothelial Growth Factor in Endometrial Cancer , 2007, Clinical Cancer Research.
[21] M. Stoffel,et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs , 2007, Nature Biotechnology.
[22] Wolfgang A. Weber,et al. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging , 2007, Proceedings of the National Academy of Sciences.
[23] S. Steinberg,et al. Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience. , 2007, Radiology.
[24] Darren H. Wakefield,et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes , 2007, Proceedings of the National Academy of Sciences.
[25] A. Elmaagacli,et al. Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia , 2007, Clinical and Experimental Medicine.
[26] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[27] G. Parker,et al. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents , 2007, British Journal of Cancer.
[28] M. Manoharan,et al. RNAi therapeutics: a potential new class of pharmaceutical drugs , 2006, Nature chemical biology.
[29] Matthias John,et al. RNAi-mediated gene silencing in non-human primates , 2006, Nature.
[30] K. Livak,et al. Real-time quantification of microRNAs by stem–loop RT–PCR , 2005, Nucleic acids research.
[31] Mark E. Davis,et al. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. , 2005, Cancer research.
[32] Benjamin M Yeh,et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] A. Judge,et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA , 2005, Nature Biotechnology.
[34] S. Akira,et al. Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7 , 2005, Nature Medicine.
[35] E. Small,et al. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Matthias John,et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.
[37] T. Tuschl,et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.
[38] M. Miyazaki,et al. Vascular endothelial growth factor secreted by replicating hepatocytes induces sinusoidal endothelial cell proliferation during regeneration after partial hepatectomy in rats. , 2001, Journal of hepatology.
[39] H. Maeda,et al. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.
[40] A. Fire,et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.
[41] M. Shibuya,et al. Increased expressions of vascular endothelial growth factor and its receptors, flt-1 and KDR/flk-1, in regenerating rat liver. , 1996, Biochemical and biophysical research communications.
[42] R. Pictet,et al. A highly sensitive method for mapping the 5' termini of mRNAs. , 1993, Nucleic acids research.
[43] F. Martin,et al. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. , 1992, Cancer research.
[44] J H Senior,et al. Fate and behavior of liposomes in vivo: a review of controlling factors. , 1987, Critical reviews in therapeutic drug carrier systems.